Publications
Oral taxanes, oral docetaxel, oral paclitaxel ...
Oral taxanes
The intravenous to oral switch of taxanes
The intravenous to oral switch of taxanes: strategies and current clinical developments. Vermunt MAC , Bergman AM , Van der Putten, Beijnen JH. Future Oncology. Published Online:24 Dec 2020.
Modulation of oral bioavailability of anticancer drugs
Modulation of oral bioavailability of anticancer drugs: from mouse to man. Schellens JH, Malingré MM, Kruijtzer CM, Bardelmeijer HA, van Tellingen O, Schinkel AH, Beijnen JH. Eur J Pharm Sci. 2000 Dec;12(2):103-10. Review.
Ritonavir reverses resistance to docetaxel in prostate cancer cells
Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel. van der Putten E, Wosikowski K, Beijnen JH, Imre G, Freund CR. Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel. Cancer Drug Resist. 2024 Jan 31;7:3.
Oral docetaxel
Phase I study with once weekly oral docetaxel - solid tumors
De Weger VA et al.: A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir. Clin Cancer Res. 2019;25:5466–74.
Phase I study with bi-daily once weekly oral docetaxel - solid tumors
De Weger VA et al.: A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. Eur J Cancer. 2017 Nov;86:217-225.
Phase I study with bi-daily once weekly oral docetaxel - prostate cancer.
Vermunt MAC, Robbrecht DGJ, Devriese LA et al.: ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study. Cancer Rep March 2021, PMID: 33709626
Phase II randomized trial comparing oral taxane to intravenous docetaxel
Vaishampayan UN, Keessen M, Dreicer R, Heath EI, Buchler T, Árkosy PF, Csöszi T, Wiechno P, Kopyltsov E, Orlov SV, Plekhanov A, Smagina M, Varlamov S, Shore ND. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. Eur J Cancer. 2024 Mar 11;202:114007.
Oral paclitaxel
Phase I study with oral paclitaxel - solid tumors
De Weger VA et al.: A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2020 Oct 5. doi: 10.1002/cpdd.880. Online ahead of print.